MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2
Completed
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Interventions
First Posted Date
2021-04-28
Last Posted Date
2024-08-09
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
129
Registration Number
NCT04862585
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Phase 1
Terminated
Conditions
Mesothelioma
Interventions
Biological: LMB-100
Procedure: Biopsy
Diagnostic Test: FDG-PET
Diagnostic Test: CT CAP
Diagnostic Test: MRI
Diagnostic Test: ECG
Diagnostic Test: Echocardiogram
First Posted Date
2021-04-12
Last Posted Date
2024-02-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2
Registration Number
NCT04840615
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PROUD Study - Preventing Opioid Use Disorders

Phase 4
Terminated
Conditions
Opioid Use
Anesthesia
Interventions
First Posted Date
2021-02-23
Last Posted Date
2023-06-22
Lead Sponsor
Emory University
Target Recruit Count
57
Registration Number
NCT04766996
Locations
🇺🇸

Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

Phase 2
Active, not recruiting
Conditions
Covid-19
Interventions
Drug: Placebo
First Posted Date
2021-01-26
Last Posted Date
2022-04-12
Lead Sponsor
Northwell Health
Target Recruit Count
56
Registration Number
NCT04724720
Locations
🇺🇸

Northwell Health, Lake Success, New York, United States

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

Phase 2
Terminated
Conditions
COVID-19
Interventions
Other: placebo
Other: chlorine dioxide
Dietary Supplement: zinc acetate
Dietary Supplement: lactoferrin, green tea extract
First Posted Date
2020-11-09
Last Posted Date
2022-09-30
Lead Sponsor
Profact, Inc.
Target Recruit Count
10
Registration Number
NCT04621149
Locations
🇺🇸

AZ Good Health Center, Tempe, Arizona, United States

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

Phase 1
Terminated
Conditions
Gastro Esophageal Reflux
Laryngomalacia
Interventions
Other: Speech Language Therapy
First Posted Date
2020-11-04
Last Posted Date
2024-08-06
Lead Sponsor
Reema Padia
Target Recruit Count
65
Registration Number
NCT04614974
Locations
🇺🇸

UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)

Phase 4
Withdrawn
Conditions
Covid19
Interventions
First Posted Date
2020-09-25
Last Posted Date
2021-12-20
Lead Sponsor
drpykessupplements.com
Registration Number
NCT04565392
Locations
🇺🇸

Pykonsult headquarters, New Fairfield, Connecticut, United States

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

Phase 1
Terminated
Conditions
Covid19
Interventions
First Posted Date
2020-09-10
Last Posted Date
2022-02-18
Lead Sponsor
Prisma Health-Upstate
Target Recruit Count
2
Registration Number
NCT04545008
Locations
🇺🇸

Prisma Health Greer Memorial Hospital, Greer, South Carolina, United States

🇺🇸

Prisma Health Baptist Easley Hospital, Easley, South Carolina, United States

🇺🇸

Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Phase 1
Completed
Conditions
Drug Interaction
Interventions
First Posted Date
2020-09-07
Last Posted Date
2021-03-09
Lead Sponsor
Calithera Biosciences, Inc
Target Recruit Count
22
Registration Number
NCT04540965
Locations
🇦🇺

Nucleus Network Brisbane Clinic (formerly Q-Pharm), Brisbane, Queensland, Australia

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Reference Treatment- BMS-986165-01
Drug: Prototype BMS-986165
Other: Alcohol
First Posted Date
2020-09-03
Last Posted Date
2021-10-06
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
56
Registration Number
NCT04536961
Locations
🇬🇧

Quotient Sciences Miami, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath